Sign In
Buy LIVN
$78.71
+0.210 (+0.268%)
At Close: Jun 22, 2026
LivaNova Reports Improved OSA Outcomes With PolySync Programming
11:16am, Wednesday, 17'th Jun 2026
LIVN's PolySync data show an 84.5% AHI response rate in OSA patients, building on OSPREY results for its aura6000 System.
LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea
10:57am, Tuesday, 16'th Jun 2026
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced new data showing that use of its PolySync™ programming algorithm inc
Jette Nygaard-Andersen Joins LivaNova Board as a New Director
01:44pm, Thursday, 11'th Jun 2026
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced the election of Jette Nygaard-Andersen to the Company's Board of Directors a
LivaNova PLC (LIVN) Shareholder/Analyst Call Prepared Remarks Transcript
11:42am, Wednesday, 10'th Jun 2026
LivaNova PLC (LIVN) Shareholder/Analyst Call Prepared Remarks Transcript
LivaNova PLC (LIVN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
11:58am, Monday, 08'th Jun 2026
LivaNova PLC (LIVN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
LivaNova Appoints Anne Liddy as Chief Legal Officer
10:00am, Friday, 05'th Jun 2026
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the appointment of Anne Liddy as Chief Legal Officer, effective Augus
LivaNova Appoints Anne Liddy as Chief Legal Officer
09:00am, Friday, 05'th Jun 2026
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the appointment of Anne Liddy as Chief Legal Officer, effective August
LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
10:00am, Thursday, 21'st May 2026
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Stefano Folli will join the Company as incoming President, Cardi
LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
09:15am, Thursday, 21'st May 2026
LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Stefano Folli will join the Company as incoming Presid
LivaNova to Present at Goldman Sachs Global Healthcare Conference in June
08:00am, Tuesday, 19'th May 2026
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the Goldman Sachs 47th Annual Global Healthcare Con
LivaNova (LIVN) Upgraded to Buy: Here's What You Should Know
01:01pm, Monday, 11'th May 2026
LivaNova (LIVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
LivaNova PLC (LIVN) Q1 2026 Earnings Call Transcript
05:01pm, Wednesday, 06'th May 2026
LivaNova PLC (LIVN) Q1 2026 Earnings Call Transcript
LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates
08:26am, Wednesday, 06'th May 2026
LivaNova (LIVN) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.88 per share a year ago.
LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
06:00am, Wednesday, 06'th May 2026
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2026 and raised full-year
Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea
05:05pm, Monday, 20'th Apr 2026
LONDON--(BUSINESS WIRE)---- $LIVN #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Annals of Internal Medicine has published an article
